Alnylam takes 10% hit on Amvuttra trial tinkering
US RNAi therapeutics company Alnylam Pharmaceuticals (Nasdaq: ALNY) took a hefty 10% hit in the stock market on Thursday.
The Boston-based firm was hurt by investors' reaction to its announcement of changes to its Phase III HELIOS-B trial of its RNAi therapeutic Amvuttra (vutrisiran) in transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM).
These trial design alterations mean that the data are now not expected until late June or early July, having previously been due to come out early this year. Analysts have speculated that the changes could reflect a lack of confidence in the study’s outcome, despite the company repeating its confidence in Amvuttra in calls with investors and the media.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze